logo

Atossa Genetics, Inc. (ATOS)



Trade ATOS now with
  Date
  Headline
6/11/2020 9:33:30 AM Atossa Therapeutics Reports Availability Of Manuscript On Results From In Vitro Testing Of COVID-19 Drug, AT-H201
5/7/2020 9:37:30 AM Atossa Report Positive Interim Results From Phase 2 Study Of Oral Endoxifen
4/20/2020 8:18:12 AM Atossa Seeks Clinical Investigation Approval To Launch COVID-19 HOPE Study
4/2/2020 8:14:49 AM Atossa Report Recent Progress With Phase 2 Study Administering Oral Endoxifen
3/2/2020 8:41:30 AM Atossa Files For Swedish Regulatory Approval To Begin Phase 2 Study Of Endoxifen
1/6/2020 8:16:43 AM Atossa Genetics Changes Corporate Name To Atossa Therapeutics, Inc.
12/19/2019 8:39:55 AM Atossa Genetics Contracts With Stockholm South General Hospital For Endoxifen
10/16/2019 8:37:55 AM Atossa Genetics Receives IRB Approval For Phase 2 Breast Cancer Study Using Intraductal Technology
9/30/2019 8:38:15 AM Atossa Reports Preliminary Results From Phase 1 Study Of Proprietary Modified-release Tablet Form Of Oral Endoxifen
9/3/2019 8:17:55 AM Atossa Genetics Completes Enrollment And Dosing In Phase 1 Clinical Trial
7/11/2019 8:39:37 AM Atossa Genetics Announces New Proprietary Modified-Release Oral Endoxifen Tablet; Begins Phase 1 Clinical Trial
6/27/2019 8:13:49 AM Atossa Genetics’ Preliminary Phase 2 Study Of Proprietary 20mg Daily Topical Z Endoxifen Achieves Primary Endpoint
3/14/2019 8:37:07 AM Atossa Genetics Announces FDA Approval Of Oral Endoxifen For “Expanded Access” As Post-Mastectomy Treatment